APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector CTDMO Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Viral Vector CTDMO Services Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchViral Vector CTDMO Services Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector CTDMO Services Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Viral Vector CTDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector CTDMO Services Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Viral Vector CTDMO Services Market Analysis and Forecast 2026-2032220 pages · $4,950 USD

Market perspective

The global Viral Vector CTDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Viral Vector CTDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Vector CTDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vector CTDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Viral Vector CTDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Viral Vector CTDMO Services market include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco, Batavia Biosciences, HALIX, Catalent Biologics and Oxford BioMedica, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Viral Vector CTDMO Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vector CTDMO Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vector CTDMO Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Vector CTDMO Services market.

Viral Vector CTDMO Services Segment by Company

AGC Biologics

Lonza

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Batavia Biosciences

HALIX

Catalent Biologics

Oxford BioMedica

Biovian

Viral Vector CTDMO Services Segment by Type

Adeno-associated Viral

Adenoviral

Lentiviral

Retroviral

Viral Vector CTDMO Services Segment by Application

Gene Therapy

Cell Therapy

Vaccine Development

Viral Vector CTDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Vector CTDMO Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Viral Vector CTDMO Services key companies, revenue, market share, and recent developments.

3. To split the Viral Vector CTDMO Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Viral Vector CTDMO Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Vector CTDMO Services significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Vector CTDMO Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector CTDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector CTDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector CTDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vector CTDMO Services industry.

Chapter 3: Detailed analysis of Viral Vector CTDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Viral Vector CTDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Viral Vector CTDMO Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Vector CTDMO Services Industry Trends Table 2. Viral Vector CTDMO Services Industry Drivers Table 3. Viral Vector CTDMO Services Industry Opportunities and Challenges Table 4. Viral Vector CTDMO Services Industry Restraints Table 5. Global Viral Vector CTDMO Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Vector CTDMO Services Revenue Share by Company (2021-2026) Table 7. Global Viral Vector CTDMO Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Viral Vector CTDMO Services Key Company Manufacturing Base & Headquarters Table 9. Global Viral Vector CTDMO Services Company, Product Type & Application Table 10. Global Viral Vector CTDMO Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Viral Vector CTDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Adeno-associated Viral Table 15. Significant Companies of Adenoviral Table 16. Significant Companies of Lentiviral Table 17. Significant Companies of Retroviral Table 18. Global Viral Vector CTDMO Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Viral Vector CTDMO Services Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Viral Vector CTDMO Services Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Viral Vector CTDMO Services Sales Value Share by Type (2021-2026) Table 22. Global Viral Vector CTDMO Services Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Gene Therapy Table 24. Significant Companies of Cell Therapy Table 25. Significant Companies of Vaccine Development Table 26. Global Viral Vector CTDMO Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Viral Vector CTDMO Services Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Viral Vector CTDMO Services Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Viral Vector CTDMO Services Sales Value Share by Application (2021-2026) Table 30. Global Viral Vector CTDMO Services Sales Value Share by Application (2027-2032) Table 31. Global Viral Vector CTDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Viral Vector CTDMO Services Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Viral Vector CTDMO Services Sales Value Share by Region (2021-2026) Table 34. Global Viral Vector CTDMO Services Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Viral Vector CTDMO Services Sales Value Share by Region (2027-2032) Table 36. Global Viral Vector CTDMO Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Viral Vector CTDMO Services Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Viral Vector CTDMO Services Sales Value Market Share by Country (2021-2026) Table 39. Global Viral Vector CTDMO Services Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Viral Vector CTDMO Services Sales Value Market Share by Country (2027-2032) Table 41. AGC Biologics Company Information Table 42. AGC Biologics Business Overview Table 43. AGC Biologics Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. AGC Biologics Viral Vector CTDMO Services Product Portfolio Table 45. AGC Biologics Recent Development Table 46. Lonza Company Information Table 47. Lonza Business Overview Table 48. Lonza Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Lonza Viral Vector CTDMO Services Product Portfolio Table 50. Lonza Recent Development Table 51. Charles River Laboratories Company Information Table 52. Charles River Laboratories Business Overview Table 53. Charles River Laboratories Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Charles River Laboratories Viral Vector CTDMO Services Product Portfolio Table 55. Charles River Laboratories Recent Development Table 56. Thermo Fisher Scientific Company Information Table 57. Thermo Fisher Scientific Business Overview Table 58. Thermo Fisher Scientific Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Thermo Fisher Scientific Viral Vector CTDMO Services Product Portfolio Table 60. Thermo Fisher Scientific Recent Development Table 61. SK pharmteco Company Information Table 62. SK pharmteco Business Overview Table 63. SK pharmteco Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. SK pharmteco Viral Vector CTDMO Services Product Portfolio Table 65. SK pharmteco Recent Development Table 66. Batavia Biosciences Company Information Table 67. Batavia Biosciences Business Overview Table 68. Batavia Biosciences Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Batavia Biosciences Viral Vector CTDMO Services Product Portfolio Table 70. Batavia Biosciences Recent Development Table 71. HALIX Company Information Table 72. HALIX Business Overview Table 73. HALIX Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. HALIX Viral Vector CTDMO Services Product Portfolio Table 75. HALIX Recent Development Table 76. Catalent Biologics Company Information Table 77. Catalent Biologics Business Overview Table 78. Catalent Biologics Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Catalent Biologics Viral Vector CTDMO Services Product Portfolio Table 80. Catalent Biologics Recent Development Table 81. Oxford BioMedica Company Information Table 82. Oxford BioMedica Business Overview Table 83. Oxford BioMedica Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Oxford BioMedica Viral Vector CTDMO Services Product Portfolio Table 85. Oxford BioMedica Recent Development Table 86. Biovian Company Information Table 87. Biovian Business Overview Table 88. Biovian Viral Vector CTDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Biovian Viral Vector CTDMO Services Product Portfolio Table 90. Biovian Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Viral Vector CTDMO Services Product Image Figure 2. Global Viral Vector CTDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector CTDMO Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vector CTDMO Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Adeno-associated Viral Image Figure 8. Adenoviral Image Figure 9. Lentiviral Image Figure 10. Retroviral Image Figure 11. Global Viral Vector CTDMO Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Viral Vector CTDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Viral Vector CTDMO Services Sales Value Share by Type (2021-2032) Figure 14. Gene Therapy Image Figure 15. Cell Therapy Image Figure 16. Vaccine Development Image Figure 17. Global Viral Vector CTDMO Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Viral Vector CTDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Viral Vector CTDMO Services Sales Value Share by Application (2021-2032) Figure 20. Global Viral Vector CTDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Viral Vector CTDMO Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Viral Vector CTDMO Services Sales Value (2021-2032) & (US$ Million) Figure 23. North America Viral Vector CTDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Viral Vector CTDMO Services Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Viral Vector CTDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Viral Vector CTDMO Services Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Viral Vector CTDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Viral Vector CTDMO Services Sales Value (2021-2032) & (US$ Million) Figure 29. South America Viral Vector CTDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Viral Vector CTDMO Services Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Viral Vector CTDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno-associated Viral
  • Adenoviral
  • Lentiviral
  • Retroviral
Applications
  • Gene Therapy
  • Cell Therapy
  • Vaccine Development
Companies covered
  • AGC Biologics
  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • SK pharmteco
  • Batavia Biosciences
  • HALIX
  • Catalent Biologics
  • Oxford BioMedica
  • Biovian

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Viral Vector CTDMO Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Viral Vector CTDMO Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Viral Vector CTDMO Services Market Dynamics
  1. 2.1 Viral Vector CTDMO Services Industry Trends
  2. 2.2 Viral Vector CTDMO Services Industry Drivers
  3. 2.3 Viral Vector CTDMO Services Industry Opportunities and Challenges
  4. 2.4 Viral Vector CTDMO Services Industry Restraints
3 Viral Vector CTDMO Services Market by Company
  1. 3.1 Global Viral Vector CTDMO Services Company Revenue Ranking in 2025
  2. 3.2 Global Viral Vector CTDMO Services Revenue by Company (2021-2026)
  3. 3.3 Global Viral Vector CTDMO Services Company Ranking (2024-2026)
  4. 3.4 Global Viral Vector CTDMO Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Viral Vector CTDMO Services Company Product Type and Application
  6. 3.6 Global Viral Vector CTDMO Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Viral Vector CTDMO Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Viral Vector CTDMO Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Viral Vector CTDMO Services Market by Type
  1. 4.1 Viral Vector CTDMO Services Type Introduction
  2. 4.1.1 Adeno-associated Viral
  3. 4.1.2 Adenoviral
  4. 4.1.3 Lentiviral
  5. 4.1.4 Retroviral
  6. 4.2 Global Viral Vector CTDMO Services Sales Value by Type
  7. 4.2.1 Global Viral Vector CTDMO Services Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Viral Vector CTDMO Services Sales Value by Type (2021-2032)
  9. 4.2.3 Global Viral Vector CTDMO Services Sales Value Share by Type (2021-2032)
5 Viral Vector CTDMO Services Market by Application
  1. 5.1 Viral Vector CTDMO Services Application Introduction
  2. 5.1.1 Gene Therapy
  3. 5.1.2 Cell Therapy
  4. 5.1.3 Vaccine Development
  5. 5.2 Global Viral Vector CTDMO Services Sales Value by Application
  6. 5.2.1 Global Viral Vector CTDMO Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viral Vector CTDMO Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Viral Vector CTDMO Services Sales Value Share by Application (2021-2032)
6 Viral Vector CTDMO Services Regional Value Analysis
  1. 6.1 Global Viral Vector CTDMO Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vector CTDMO Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Viral Vector CTDMO Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Viral Vector CTDMO Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Viral Vector CTDMO Services Sales Value (2021-2032)
  7. 6.3.2 North America Viral Vector CTDMO Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Viral Vector CTDMO Services Sales Value (2021-2032)
  10. 6.4.2 Europe Viral Vector CTDMO Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Viral Vector CTDMO Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Viral Vector CTDMO Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Viral Vector CTDMO Services Sales Value (2021-2032)
  16. 6.6.2 South America Viral Vector CTDMO Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Viral Vector CTDMO Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Viral Vector CTDMO Services Sales Value Share by Country, 2025 VS 2032
7 Viral Vector CTDMO Services Country-level Value Analysis
  1. 7.1 Global Viral Vector CTDMO Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Vector CTDMO Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Viral Vector CTDMO Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Viral Vector CTDMO Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Viral Vector CTDMO Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Viral Vector CTDMO Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Viral Vector CTDMO Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AGC Biologics
  2. 8.1.1 AGC Biologics Company Information
  3. 8.1.2 AGC Biologics Business Overview
  4. 8.1.3 AGC Biologics Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AGC Biologics Viral Vector CTDMO Services Product Portfolio
  6. 8.1.5 AGC Biologics Recent Developments
  7. 8.2 Lonza
  8. 8.2.1 Lonza Company Information
  9. 8.2.2 Lonza Business Overview
  10. 8.2.3 Lonza Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lonza Viral Vector CTDMO Services Product Portfolio
  12. 8.2.5 Lonza Recent Developments
  13. 8.3 Charles River Laboratories
  14. 8.3.1 Charles River Laboratories Company Information
  15. 8.3.2 Charles River Laboratories Business Overview
  16. 8.3.3 Charles River Laboratories Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Charles River Laboratories Viral Vector CTDMO Services Product Portfolio
  18. 8.3.5 Charles River Laboratories Recent Developments
  19. 8.4 Thermo Fisher Scientific
  20. 8.4.1 Thermo Fisher Scientific Company Information
  21. 8.4.2 Thermo Fisher Scientific Business Overview
  22. 8.4.3 Thermo Fisher Scientific Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Thermo Fisher Scientific Viral Vector CTDMO Services Product Portfolio
  24. 8.4.5 Thermo Fisher Scientific Recent Developments
  25. 8.5 SK pharmteco
  26. 8.5.1 SK pharmteco Company Information
  27. 8.5.2 SK pharmteco Business Overview
  28. 8.5.3 SK pharmteco Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SK pharmteco Viral Vector CTDMO Services Product Portfolio
  30. 8.5.5 SK pharmteco Recent Developments
  31. 8.6 Batavia Biosciences
  32. 8.6.1 Batavia Biosciences Company Information
  33. 8.6.2 Batavia Biosciences Business Overview
  34. 8.6.3 Batavia Biosciences Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Batavia Biosciences Viral Vector CTDMO Services Product Portfolio
  36. 8.6.5 Batavia Biosciences Recent Developments
  37. 8.7 HALIX
  38. 8.7.1 HALIX Company Information
  39. 8.7.2 HALIX Business Overview
  40. 8.7.3 HALIX Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 HALIX Viral Vector CTDMO Services Product Portfolio
  42. 8.7.5 HALIX Recent Developments
  43. 8.8 Catalent Biologics
  44. 8.8.1 Catalent Biologics Company Information
  45. 8.8.2 Catalent Biologics Business Overview
  46. 8.8.3 Catalent Biologics Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Catalent Biologics Viral Vector CTDMO Services Product Portfolio
  48. 8.8.5 Catalent Biologics Recent Developments
  49. 8.9 Oxford BioMedica
  50. 8.9.1 Oxford BioMedica Company Information
  51. 8.9.2 Oxford BioMedica Business Overview
  52. 8.9.3 Oxford BioMedica Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Oxford BioMedica Viral Vector CTDMO Services Product Portfolio
  54. 8.9.5 Oxford BioMedica Recent Developments
  55. 8.10 Biovian
  56. 8.10.1 Biovian Company Information
  57. 8.10.2 Biovian Business Overview
  58. 8.10.3 Biovian Viral Vector CTDMO Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biovian Viral Vector CTDMO Services Product Portfolio
  60. 8.10.5 Biovian Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst